Why is the Avita Medical share price rocketing 24% today?

This healthcare share is ending the week on a very positive note. But why?

| More on:
Vanadium Resources share price person riding rocket indicating share price increase

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Avita Medical Inc (ASX: AVH) share price is catching the eye on Friday.

In morning trade, the regenerative medicine company's shares are up 24% to $3.96.

Why is the Avita Medical share price rocketing?

Investors have been picking up Avita Medical's shares this morning after it released its third quarter update and revealed strong top line growth.

Here's a summary of how it performed for the three months ended 30 September:

  • Commercial revenue up 51% to US$13.5 million
  • Gross margin of 84.5% for the quarter
  • Operating expenses up 48% to US$21 million
  • Net loss widened 55% to US$8.7 million
  • Cash on hand of US$60.1 million

Despite its sizeable loss, management believes the regenerative medicine company is well-positioned and has sufficient cash to meet its profitability goals. This could explain the strong rise in the Avita Medical share price today.

This should be supported by the Recell Go product, which management appears confident will be granted US FDA approval next year.

The company's chief executive officer, Jim Corbett, commented:

We continue to execute our growth strategy, paving the way to profitability. We are diligently working through supplemental in-house testing to support the FDA's review of our PMA supplement for RECELL GO. Once complete, we expect to submit a response to the FDA's open questions on February 28, 2024. Under the Breakthrough Device program, we anticipate FDA approval on May 30, 2024, which positions us for a launch the following day.

This sentiment was echoed by its chief financial officer, David O'Toole, he adds:

We have achieved significant commercial revenue growth rates for the last three quarters of 40%, 42% and 51%, respectively, over the same periods in the previous year. Further, we remain confident that our cash reserves position us to achieve our goals and reach profitability in 2025.

Looking ahead, the company expects its strong top-line growth to continue. It is guiding to fourth-quarter commercial revenue growth of 64% to 73% over the prior corresponding period.

Following today's gain, the Avita Medical share price is now up 100% in 2023.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Avita Medical. The Motley Fool Australia has recommended Avita Medical. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Sell and buy on red cubes on a digital screen.
Technology Shares

This ASX 200 high-flyer dropped 15%, is it time to jump in?

Analysts remain positive due to the company's strong fundamentals.

Read more »

Focused man entrepreneur with glasses working, looking at laptop screen thinking about something intently while sitting in the office.
Healthcare Shares

Are CSL shares a buy after their heavy decline?

Let's see what one broker is saying about the biotech giant.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Why are Telix Pharmaceuticals shares diving today?

Shares in this up-and-coming drug company are under pressure over law suits filed in the US.

Read more »

A young woman wearing a red and white striped t-shirt puts her hand to her chin and looks sideways as she wonders whether to buy ASX shares
Healthcare Shares

CSL, Sonic, and Sigma Healthcare shares: Buy, hold, or sell?

Analysts share their ratings and opinions on 3 large-cap ASX 200 healthcare stocks.

Read more »

young female doctor with digital tablet looking confused.
Healthcare Shares

Down 38% in a year, are CSL shares now a buy?

A leading investment expert delivers his verdict on CSL shares.

Read more »

A woman holds her hand out under a graphic hologram image of a human brain with brightly lit segments and section points.
Healthcare Shares

This Cochlear-backed ASX aspirant will be targeting an epilepsy market worth north of $1 billion

This company is looking to raise $125 million to help commercialise its epilepsy monitoring technology.

Read more »

Surgeon looking at a monitor in an operating room.
Share Market News

Is the only way up for this ASX small-cap healthcare stock?

Bigger returns could be coming for this ambitious small-cap.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Monash IVF has named a new Managing Director to help right the ship

Monash IVF has named a new leader, but she will not start in the top job for some time.

Read more »